Healthcare / Pharmaceutical RetailersBSE
$25.12
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-6.5M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$219M
P/E
73.9x
↑EV/EBITDA
27.8x
↑ROE
3.4%
↑Gross Margin
54.1%
↑Debt/Equity
0.34
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.5%
FCF CAGR
—
FCF margin
-87.5%
FCF / Net income
-18.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $62.7M · net income $3.0M · FCF $-54.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.7M | $62.7M | $59.4M | $49.4M | $53.4M |
| Net Income | $3.0M | $3.0M | $5.0M | $3.6M | $1.2M |
| EBITDA | $8.9M | $8.9M | $12.0M | $8.7M | $6.2M |
| EPS | 0.34 | 0.34 | 0.57 | 0.41 | 0.14 |
| Gross Margin | 54.1% | 54.1% | 60.1% | 52.9% | 51.9% |
| Operating Margin | 7.6% | 7.6% | 14.0% | 10.7% | 5.4% |
| Net Margin | 4.7% | 4.7% | 8.4% | 7.3% | 2.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.34 | 0.34 | 0.31 | 1.27 | 2.03 |
| Current Ratio | 2.65 | 2.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-54.9M | $-54.9M | $-6.5M | $4.0M | $417000.00 |
| Returns | |||||
| ROE | 3.4% | 3.4% | 15.0% | 26.3% | 12.1% |
| Valuation | |||||
| P/E | 73.88 | 73.88 | — | — | — |
| EV/EBITDA | 27.76 | 27.76 | — | — | — |
| P/B | 2.49 | 2.49 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 5.6% | 5.6% | 20.3% | -7.6% | — |
| EPS Growth | -40.8% | -40.8% | 39.4% | 195.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
87.2%
EPS terminal req.
$2.23
Spread vs growth
-128.0%
5Y implied EPS CAGR
51.3%
EPS terminal req.
$2.70
Spread vs growth
-92.1%
10Y implied EPS CAGR
29.0%
EPS terminal req.
$4.34
Spread vs growth
-69.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+20.2%
Start / end P/E
38.3x → 77.8x
EPS bridge
0.57 → 0.34
Residual
-42.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.